Delivery Order SPE2DB20D2014-SPE2DB25FC96W
- Not listed
- The Defense Logistics Agency (DLA) awarded AmerisourceBergen Drug Corp a delivery order valued at $3,216.66 on August 5, 2025, for the supply of Ozempic 1 mg/dose (4 mg/3 ml) in 3 ml vials. This competitively awarded, firm fixed-price delivery order is set to be completed by August 6, 2025, with performance conducted at AmerisourceBergen's facility in Conshohocken, Pennsylvania. The award represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA...
- The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp on July 28, 2025, for the supply of Ozempic 1 mg/dose (4 mg/3 mL) 3 mL vials, with a ceiling value of $3,494.97. This is a firm fixed-price, non-set-aside contract with an ultimate completion date of July 29, 2025, and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The award represents a delivery order issued under a larger federal contract vehicle...
- The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp for the supply of Ozempic 1 mg/dose (4 mg/3 mL) prefilled pens with a ceiling value of $53,874.20. The contract was executed on September 2, 2025, with an ultimate completion date of September 3, 2025, and utilized firm fixed-price pricing under a non-set-aside competitive procurement. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, is a major pharmaceutical distributor serving as a...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $19,681.34 to AmerisourceBergen Drug Corp for the supply of Ozempic 1 mg/dose (4 mg/3 mL) in 3 mL vials. This competitively awarded, firm fixed-price contract was executed on August 11, 2025, with an ultimate completion date of August 12, 2025, and will be performed at the vendor's corporate office location in Conshohocken, Pennsylvania. The contract carries no set-aside designation, indicating it was awarded through open...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $1,879.98 to AmerisourceBergen Drug Corp for the supply of Ozempic 2 mg/dose (8 mg/3 mL) in 3 mL vials. This contract, executed on August 25, 2025, with an ultimate completion date of August 26, 2025, is structured as a firm fixed-price delivery order with no set-aside designation. The pharmaceutical product will be delivered to Conshohocken, Pennsylvania, the location of AmerisourceBergen's corporate headquarters and...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 27, 2025, for the supply of Ozempic 2 mg/dose (8 mg/3 mL) in 3 mL vials, with a ceiling value of $31,785.02. This competitively awarded, non-set-aside contract utilizes firm fixed pricing and is classified as a delivery order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX and valued at $999,999,999.00 through December 2026. The...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 18, 2025, for the supply of Ozempic 1 mg/dose (4 mg/3 mL) 3 mL vials with a ceiling value of $29,042.05. This firm fixed-price delivery order, which is set to be completed by August 19, 2025, will be fulfilled from the vendor's location in Conshohocken, Pennsylvania. The award represents a competitive procurement with no set-aside designation, reflecting AmerisourceBergen's demonstrated capability to...
- The Defense Logistics Agency awarded a delivery order valued at $25,944.44 to AmerisourceBergen Drug Corp for the supply of Ozempic 1 mg/dose (4 mg/3 ml) 3ml vials under a firm fixed-price contract. The award was made on August 4, 2025, with an ultimate completion date of August 5, 2025, and is non-set-aside, indicating it was competitively awarded. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, serves as a critical pharmaceutical distributor for federal medical procurement,...
- The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp for the supply of Ozempic 1 mg/dose (4 mg/3 mL) 3 mL vials with a ceiling value of $2,819.97. This non-set-aside, competitively awarded contract employs firm fixed pricing and carries an ultimate completion date of September 15, 2025. The order will be fulfilled from AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, the company's headquarters. This delivery order is issued...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $19,452.93 to AmerisourceBergen Drug Corp for the supply of Ozempic 2 mg/dose (8 mg/3 mL) in 3 mL vials. This contract, which was competitively awarded with no set-aside designation, features firm fixed pricing and is scheduled for completion by July 23, 2025. The award was made on July 22, 2025, with performance to take place at AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. This delivery order is...
- SPE2DB20D2014Indefinite Delivery Contract
- SPE2DB20D2014-SPE2DB25FC96WDelivery Order
The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp for the supply of Ozempic 1 mg/dose (4 mg/3 mL) 3 mL vials valued at $27,509.02. This non-competitive delivery order was awarded on September 10, 2025, with an ultimate completion date of September 11, 2025, and will be performed at the contractor's facility in Conshohocken, Pennsylvania. The contract employs firm fixed pricing and represents a continuation of AmerisourceBergen's role as a critical pharmaceutical distributor for federal medical procurement. This delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), a $999.9 billion comprehensive pharmaceutical support vehicle running through December 2026. As the prime contractor on this IDC, AmerisourceBergen supplies a broad range of pharmaceutical products and medical commodities to support military healthcare systems globally, including medications serving the Defense Health Agency, U.S. Coast Guard, and other federal healthcare entities. The award of Ozempic, a diabetes medication, reflects the company's extensive portfolio of specialty pharmaceuticals and its position as a major vendor supporting federal medical supply chain requirements.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $27.5k | 9/10/25 |